Economics and risks of FDA's Quality management maturity rating programme
The introduction of pharmaceutical manufacturing quality ratings by the FDA under its Quality Management Maturity (QMM) programme has the potential to reduce drug shortages and improve pharmaceutical company financial performance. Here, Dr Clifford Rossi of the University of Maryland explains.
Source: europeanpharmaceuticalreview.com